University of Pittsburgh Cancer Institute gets NCI preclinical research contract

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

THE UNIVERSITY OF PITTSBURGH CANCER INSTITUTE, partnered with UPMC CancerCancer, received a contract from NCI to perform preclinical research for the development of new cancer drugs. This commitment could bring up to $10 million in research projects to UPCI over the next five years.

Julie Eiseman, professor of pharmacology and chemical biology, and Jan Beumer, associate professor of pharmaceutical sciences and medicine, will serve as co-principal investigators on the research contract. They also hold a previous NCI preclinical contract, which will conclude next year. The researchers do not yet know specifically what potential drugs they’ll be investigating or in which indications.

YOU MAY BE INTERESTED IN

For decades, we have faced a central challenge in colorectal cancer screening. One in three eligible Americans—over 50 million people—remain unscreened despite established methods like colonoscopy or stool-based tests existing for decades. This gap persists even though early detection saves lives, and even as colorectal cancer is now the number one cancer killer for Americans under 50.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login